Successful therapy of macrophage activation syndrome with dexamethasone palmitate

Abstract

Macrophage activation syndrome (MAS) is a severe and potential life-threatening complication of childhood systemic inflammatory disorders. Corticosteroids are commonly used as the first-line therapy for MAS. We report four patients with MAS who were successfully treated with dexamethasone palmitate (DexP), a liposome-incorporated dexamethasone, much more efficient than free corticosteroids. DexP effectively inhibited inflammation in MAS patients in whom the response to pulse methylprednisolone was not sufficient to manage their diseases. DexP was also effective as the first-line therapy for MAS. Based on these findings, DexP is an effective therapy in treating MAS patients.

Keywords:

• Dexamethasone palmitate
• Systemic juvenile idiopathic arthritis
• Macrophage activation syndrome

Conflict of interest

None.

Funding

We have not received funding for this study.